

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT – RESEARCH AND DEVELOPMENT UPDATE**

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Nanjing Legend Biotech Co., Ltd.\* 南京傳奇生物科技股份有限公司 (“**Nanjing Legend**”), a wholly-owned subsidiary of the Company, has achieved promising results in its research and development in immunotherapy technology for cancer cure.

Nanjing Legend has been focusing on the research and development of chimeric antigen receptor T (“**CAR-T**”) cell technology in immunotherapy. Nanjing Legend has collaborated with a 3A hospital in China and provided proprietary CAR-T cell technology to treat Multiple Myeloma for clinical research. The Board is pleased to announce that the clinical research yields promising results.

Multiple Myeloma is a fatal plasma cell neoplasm affecting one to five per 100,000 individuals. As CAR-T cell therapy is demonstrating clinical efficacy in treating certain kinds of leukemia and lymphoma, increasing attempts in developing CAR-T cell therapy to treat Multiple Myeloma have been made worldwide. The Group believes that CAR-T cell technology has significant potential in clinical cancer therapeutics, the promising clinical research results further boost the Group's plan to capture the growth opportunities in the clinical research services market by continuing its research and development in cancer immunotherapy and expanding into the development and application of CAR-T cell therapy in the future.

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 28 October 2016

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*